Q-omics provides the consensus-scored KRTAP2-2 profile across patient tissues and cancer cell-line models. KRTAP2-2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, KRTAP2-2 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, KRTAP2-2 RNA expression shows 2,821 significant pathway-activity associations, with the highest sampling consensus in LUSC. Together, these results highlight OV, KIRC, and LUSC as cancer lineages where KRTAP2-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTAP2-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTAP2-2 survival associations across molecular data types. KRTAP2-2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTAP2-2 RNA expression–survival associations across cancer types. High KRTAP2-2 expression shows unfavorable associations in OV, BLCA, LIHC, HNSC, SKCM and TGCT. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for KRTAP2-2 RNA expression.
This table summarizes KRTAP2-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KRTAP2-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTAP2-2 shows lower tumor expression in KIRC and higher tumor expression in BRCA. The KIRC box plot shows higher KRTAP2-2 RNA expression in normal versus tumor tissue (log2 FC = −0.019, t-test p < 0.001).
This table shows molecular features associated with KRTAP2-2 in patient tissues and cancer cell lines. In patient samples, KRTAP2-2 shows the broadest associations at the RNA and protein expression levels, with LUSC recurring as the lineage with the largest associated feature set. In cancer cell lines, KRTAP2-2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
